Galina F Denisova

USPTO Granted Patents = 8 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 2)

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 44(Granted Patents)

Company Filing History:

Years Active: 2014-2024

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11970545 - T cell-antigen coupler with Y182T mutation and methods of uses thereof (2024-04-30),

2. 11643472 - T cell-antigen coupler with Y182T mutation and methods and uses thereof (2023-05-09),

3. 11421014 - Trifunctional T cell-antigen coupler and methods and uses thereof (2022-08-23),

4. 11198737 - T cell-antigen coupler with Y177 mutation and methods of uses thereof (2021-12-14),

5. 11008376 - Trifunctional T cell-antigen coupler and methods and uses thereof (2021-05-18),

6. 11001621 - Trifunctional T cell-antigen coupler and methods and uses thereof (2021-05-11),

7. 10435453 - Trifunctional T cell-antigen coupler and methods and uses thereof (2019-10-08),

8. RE44747 - Mapping and reconstitution of a conformational discontinuous binding surface (2014-02-03),

Title: Galina F Denisova: Innovator in T Cell Engineering

Introduction

Galina F Denisova is a prominent inventor based in Hamilton, Canada. She has made significant contributions to the field of immunology, particularly in the engineering of T cells for enhanced therapeutic applications. With a total of seven patents to her name, her work is paving the way for advancements in cancer treatment and immune response modulation.

Latest Patents

Denisova's latest patents include a groundbreaking invention titled "T cell-antigen coupler with Y182T mutation and methods of uses thereof." This trifunctional molecule comprises a target-specific ligand, a ligand that binds a protein associated with the T cell receptor (TCR) complex, and a T cell receptor signaling domain polypeptide. The ligand that binds a protein associated with the TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen-specific activation of numerous T cell functions, including cytokine production, degranulation, and cytolysis.

Career Highlights

Denisova's career is marked by her innovative research and development in T cell engineering. Her work has not only resulted in multiple patents but has also contributed to the understanding of T cell functions and their potential applications in immunotherapy. She is affiliated with McMaster University, where she continues to advance her research.

Collaborations

Throughout

This text is generated by artificial intelligence and may not be accurate.